Dopaminergic Mechanisms in Depression and Antidepressant Drug Effects

1. Allard, P., Norlen M.: Caudate nucleus D2 receptors in depressed suicide victims. Neuropsychobiology, 44, 2001, pp. 70-73.

2. Asberg, M., Thoren, P., Traskman, L., Bertilsson, L., Ringberger, V.: Serotonin depression- a biochemical subgroup within the affective disorders? Science, 191 (4226), 1976, pp. 478-80.

3. Berk, M., Dodd, S., Kauer-Sant’anna, M., Malhi, G. S., Bourin, M., Kapczinski, F., Norman, T.: Dopamine dysregulation syndrome: implications for a dopamine hypothesis of bipolar disorder. Acta Psychiatr. Scand. Suppl., 434, 2007, pp. 41-49.

4. Bonci, A., Hopf, F. W.: The dopamine D2 receptor: New surprises from an old friend. Neuron, 47, 2005, 3, pp. 335-338.

5. Brown, A. S., Gershon, S.: Dopamine and depression. J. Neural. Transm., 91, 1993, pp. 75-109.

6. Brugue, E., Vieta, E.: Atypical antipsychotics in bipolar depression: neurobiological basis and clinical implications. Prog. Neuropsychopharmacol. Biol. Psychiatry, 31, 2007, 1, pp. 275-282.

7. Dailly, E., Chenu, F., Renard, C. E.: Dopamine, depression and antidepressants. Fundamental & Clin.l Pharmacol., 18, 2004, pp. 601-607.

8. Di Chiara, G., Loddo, P., Tanda, G.: Reciprocal changes in prefrontal and limbic dopamine responsiveness to aversive and rewarding stimuli after chronic mild stress: implications for the psychobiology of depression. Biol. Psychiatry, 46, 1999, 12, pp. 1624-1633.

9. Di Matteo, V., De Blasi, A., Di Giulio, C., Esposito, E.: Role of 5-HT2C receptors. Trends Pharmacol. Sci., 22, 2001, 5, pp. 229-232.

10. Dunlop, B.W., Nemeroff, Ch. B.: The role of dopamine in the pathophysiology of depression. Arch. Gen. Psychiatry, 3, 2007, pp. 327-337.

11. Elhwuegi, A. S.: Central monoamines and their role in major depression. Progress Neuro-Psychopharmacol. Biol. Psychiatry, 28, 2004, 3, pp. 435-451.

12. Engstrom, G., Alling, C., Blennow, K. et al.: Reduced cerebrospinal HVA concentrations and HVA/5-HIAA ratios in suicide attempters - Monoamine metabolites in 120 suicide attempters and 47 controls. Eur. Neuropsychopharmacol., 9, 1999, 5, pp. 399-405.

13. Fiorino, D. F., Coury, A., Phillips, A. G.: Dynamic changes in nucleus accumbens dopamine efflux during the Coolidge effect in male rats. J. Neurosci., 17,1997, 12, pp. 4849-4855

14. Foley, K. F., DeSanty K. P., Kast, R. E.: Bupropion: pharmacology and therapeutic applications. Expert Rev Neurotherapeut, 6, 2006, pp. 1249-1265.

15. Garattini, S.: Pharmacology of amineptine, an antidepressant agent acting on thedopaminergic system: a review. Int. Clin. Psychopharmacol., 12, Suppl 3, 1997, pp. S15-S19.

16. Hamner, M. B., Diamond, B. I.: Plasma dopamine and norepinephrine correlations with psychomotor retardation, anxiety, and depression in non-psychotic depressed patients: A pilot study. Psychiatry Res., 64, 1996, 3, pp. 209-211.

17. Hejny, S. E., Lucki, I., Gatto, G., Singh, A., Thornley, C., Matasi, J., Kong, N., Smith, J. E., Davies, H. M. L., Dworkin, S. I.: Potential antidepressant. Effects of novel tropane compounds, selective for serotonin or dopamine transporters. J. Pharmacol. Exp. Therap., 282, 1997, 21, pp. 727-733.

18. Kapur, S., Mann, J. J.: Role of the dopaminergic system in depression. Biol. Psychiatry, 32, 1992, 1, pp. 1-17.

19. Kerwin, R.: From pharmacological profiles to clinical outcomes. Int. Clin. Psychopharmacol., 15, Suppl 4, 2000, pp. S1-S4.

20. Klimek, V., Schenck, J. E., Han, H., Stockmeier, C. A., Ordway, G. A.: Dopaminergic abnormalities in amygdaloid nuclei in major depression: a postmortem study. Biol. Psychiatry, 52, 2002, pp. 740-748.

21. Koob, G F.: Hedonic valence, dopamine, and motivation. Mol. Psychiatry, 1, 1996, pp. 186-189.

22. Lammers, C. H., Diaz, J., Schwartz, J. C., Sokoloff, P.: Selective increase of dopamine D3 receptor gene expression as a common effect of chronic antidepressant treatments. Mol. Psychiatry, 5, 2000, pp. 378–388.

23. Lapin, I. P., Oxenkrug, G. F.: Intensification of the central serotoninergic processes as a possible determinant of the thymoleptic effect. Lancet, 1, (7586), 1969, pp. 132-136.

24. Lemke, M. R.: Antidepressant effects of dopamine agonists. Experimental and clinical findings. Nervenarty, 78, 2007, 1, pp. 31-38.

25. Levant, B.: The D3 dopamine receptor: Neurobiology and potential clinical relevance. Pharmacol. Rev., 49, 1997, pp. 231-252.

26. McLean, A., Rubinsztein, J., Robbins, T., Sahakian, B.: The effects of tyrosine depletion in normal healthy volunteers: implications for unipolar depression. Psychopharmacol., 171, 2004, pp. 286-297.

27. Meyer, J. H., Kapur, S., Eisfeld, B., Brown, G. M., Houle S. et al.: The effect of paroxetine on 5-HT2A receptors in depression: An [18F]setoperone iImaging Study. Am. J. Psychiatry, 158, 2001, 1, pp. 78-85.

28. Muscat, R., Papp, M., Willner, P.: Antidepressant-like effects. of dopamine agonists in an animal model of depression. Biol. Psychiatry, 31, 1992, pp. 937-946.

29. Ossowska, G., Nowak, G., Klenk-Majewska, B., Danilczuk, Z., Zebrowska-Lupina, I.: Effect of imipramine on brain D-1 and 5-HT-2A receptors in a chronic unpredictable stress model in rats. Polish J. Pharmacol., 54, 2002, 2, pp. 89-93.

30. Pani, L., Gessa, G. L.: Evolution of the dopaminergic system and its relationships with the psychopathology of pleasure. Int. J. Clin. Pharmacol. Res., 17, 1997, 2-3, pp. 55-58.

31. Papakostas, G. I.: Dopaminergic-based pharmacotherapies for depression. Eur. Neuropsychopharmacol., 16, 2006, pp. 391-402.

32. Park, S. K., Nguyen, M. D., Fischer, A., Luke, M. P. et al.: Par-4 links dopamine signaling and depression. Cell, 122, 2005, 2, pp. 275-287.

33. Rampello, L., Nicoletti, G., Rafaele, R.: Dopaminergic hypothesis for retarded depression: a symptom profile for predicting therapeutical responses. Acta Psychiatrica Scand., 84, 1991, pp. 552-554.

34. Randrup, A., Braestrup, C.: Uptake Inhibition of biogenic amines by newer antidepressant drugs: Relevance to the dopamine hypothesis of depression. Psychopharmacol., 53, 1997, pp. 309-314.

35. Robbins, T. W., Everitt, B. J.: Neurobehavioural mechanisms of reward and motivation. Current Opinion in Neurobiology, 6, 1996, pp. 228-236.

36. Roy, A., Pickar, D., Dejong, J. et al.: Norepinephrine and its metabolites in cerebrospinal-fluid, plasma, and urine – relationship to hypothalamic-pituitary-adrenal axis function in depression. Arch. Gen. Psychiatry, 45, 1988, 9, pp. 849-857.

37. Roy, A., Karoum, F., Pollack, S.: Marked reduction in indexes of dopamine metabolism among patients with depression who attempt suicide. Arch. Gen. Psychiatry, 49, 1992, 6, pp. 447-450.

38. Saxon, A. J.: Dopamine and depression. Arch. Gen. Psychiatry, 64, 2007, 9, pp. 1101-1101.

39. Scatton, B., Claustre, Y., Cudennec A.: Review. Int. Clin. Psychopharmacol., 12 Suppl 2, 1997, pp. S29-S36.

40. Schildkraut, J. J., Gordon, E. K., Durell, J.: Catecholamine metabolism in affective disorders. I. Normetanephrine and VMA excretion in depressed patients treated with imipramine. J. Psychiatr. Res., 3, 1965, 4, pp. 213-28

41. Schoemaker, H., Claustre, Y., Fage, D.: J. Pharmacol. Exp. Therap., 280, 1997, 1, pp. 83-97.

42. Seeman, P., Van Tol, H. H.: Trends pharmacol. Sci., 15, 1994, pp. 264-270.

43. Sokoloff, P., Diaz, J., Le Foll, B., Guillin, O., Leriche, L., Bezard, E., Gross, C.: CNS & Neurol. l Disorders Drug Torgets, 5, 2006, pp. 25-43.

44. Stahl S. M.: Essential psychopharmacology neuroscientific basis and practical applications. Cambridge University Press, 2000.

45. Stahl S. M.: V: The Prescriber´s guide – antidepressants. Cambridge University Press, 2006, pp. 171-178.

46. Syvalahti, E., Penttila, J., Majasuo, H., Palvimaki, E .P., Laakso, A., Hietala, J.: Pharmacopsychiatry, 39, 2006, 1, pp. 1-8.

47. Willner, P.: Validity, reliability and utility of the chronic mild stress model of depression: a 10-year review and evaluation. Psychopharmacology, 134, 1997, 4, pp. 319-329.

48. Willner, P., Hale, A. S., Argyropoulosc, S.: Dopaminergic mechanism of antidepressant action in depressed patients. J. Affect. Disorders, 86, 2005, 1, pp. 37-45.